Skip to content
Gregg Girvan & Grant Rigney /

Beware the Hype Over Two New Alzheimer’s Drugs

They could cost taxpayers billions while potentially delivering few benefits.
FRANCE-ALZHEIMER-VILLAGE
A volunteer helps an Alzheimer’s patient. (Photo by Phillipe Lopez/AFP/Getty Images.)

Two new Alzheimer’s drugs are being touted as having potentially significant effects on cognitive decline, but a careful review of the clinical trial results suggests that their efficacy is actually questionable. If Medicare opts to cover them, taxpayers will be on the hook for expensive drugs that might not provide concordant benefits.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Gregg Girvan is a resident fellow for the Foundation for Research on Equal Opportunity.

Grant Rigney is a visiting fellow at the Foundation for Research on Equal Opportunity and a medical student at Harvard Medical School.

More We Think You’d Like

Loading